SUMMARY
Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells in vitro and their decreased proliferation in vivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.
INTRODUCTION
Arginine methylation is a common posttranslational modification that regulates the function of a wide range of proteins. There are ten members of the protein arginine methyltransferase (PRMT) family, eight of which catalyze the formation of either asymmetric dimethylarginine (the type I enzymes) or symmetric dimethylarginine (the type II enzymes) (Bedford and Clarke, 2009 ). The type I protein arginine methyltransferase 4 (PRMT4), also called coactivator-associated arginine methyltransferase 1 (CARM1), functions as a coactivator of nuclear hormone receptors as well as other transcription factors including p53 , NF-kappa B (Covic et al., 2005) , b-catenin (Koh et al., 2002) , and Mef2c (Chen et al., 2002) . PRMT4 can methylate the transcriptional coactivator p300 (Xu et al., 2001; Lee et al., 2011) and several histone substrates, in particular, H3R17 and H3R26 (Daujat et al., 2002; Schurter et al., 2001) . PRMT4 plays an important role in a number of biological processes including muscle cell differentiation (Chen et al., 2002) , T cell development , and adipocyte differentiation (Yadav et al., 2008) . PRMT4 maintains embryonic stem cell (ESC) pluripotency and inhibits ESC differentiation (Torres-Padilla et al., 2007; Wu et al., 2009) . Although other members of the PRMT family have been implicated in hematopoiesis and acute leukemia (Zhao et al., 2008; Cheung et al., 2007; Liu et al., 2011) , little is known about the role of PRMT4 in normal or malignant hematopoiesis.
RUNX1 (also known as AML1) is a transcription factor that binds to a consensus binding sequence (CBS) PyGpyGGTPy (Py = pyrimidine) in the regulatory regions of promoters and enhancers of genes that play important roles in hematopoiesis. RUNX1 knockout mice die between embryonic day (E) 11.5 and E13.5 with a complete lack of fetal liver (i.e., definitive) hematopoiesis (Okuda et al., 1996) , whereas conditional deletion of RUNX1 in adult mice results in profound lineage-specific abnormalities, including a block in lymphoid development and + cells were transduced with lentiviruses expressing a control (scrambled) shRNA or one of two shRNAs directed against PRMT4. GFP-positive cells were sorted 3 days after transfection and collected to perform qRT-PCR and western blot analyses. qRT-PCR data represent the mean ± SD of the three independent experiments. **p < 0.01 by Student's t test. Tubulin served as the loading control.
reduced megakaryocytic production, with little effect on adult hematopoietic stem cells (HSCs) . RUNX1 is one of the most frequently altered genes in acute leukemia, either by chromosomal translocations such as the t(8;21) (Blyth et al., 2005) or by point mutations or deletions that occur in 4%-10% of patients with sporadic or therapy-related myelodysplastic syndrome and acute myelogenous leukemia (AML) (Osato, 2004) . Furthermore, RUNX1 point mutations are found in affected individuals with the inherited FPD/AML syndrome (familial platelet disorder with propensity to AML) (Song et al., 1999) . Posttranslational modifications, including ubiquitination, phosphorylation, acetylation, and methylation fine-tune RUNX1 function (Wang et al., 2009 ); for instance, arginine methylation of an RTAMR motif in RUNX1 by PRMT1 abrogates SIN3A binding, thereby potentiating RUNX1-dependent transcriptional activation of its target genes (Zhao et al., 2008) . Similarly, microRNAs such as miR-17-5p, miR-20a, and miR-106a can regulate RUNX1 protein expression and thereby control aspects of hematopoietic cell differentiation (Fontana et al., 2007) . The myeloid-specific microRNA-223 (miR-223) has been shown to affect granulocytic differentiation. Loss of miR-223 impairs granulocytic maturation (Johnnidis et al., 2008) , whereas miR-223 overexpression promotes myeloid differentiation (Fazi et al., 2005) . miR-223 expression has been shown to be transcriptionally regulated by NF-IA (Fazi et al., 2005) , by C/EBPs and PU.1 (Fukao et al., 2007) and by E2F1 (Pulikkan et al., 2010) . Fazi et al. reported that the AML1-ETO fusion protein represses miR-223 expression by binding to a RUNX CBS located upstream of the pre-miR-223 (Fazi et al., 2007) . They, and others, have found that miR-223 expression is downregulated in AML patient samples (Fazi et al., 2007; Pulikkan et al., 2010; Eyholzer et al., 2010) .
In this study, we have identified PRMT4 as a regulator of the myeloid differentiation process in stem/progenitor human hematopoietic cells (HSPCs). PRMT4 forms a regulatory loop with miR-223, to reciprocally suppress the expression of each other during myeloid differentiation. We also show that RUNX1 is a substrate of PRMT4 and that methylation of RUNX1 by PRMT4 (on arginine 223 [R223]) leads to the recruitment of a DPF2-containing repressor complex that binds critical miR-223 transcriptional regulatory elements (that are distinct from the element identified by Fazi et al., 2007) and represses miR-223 expression. A decrease in PRMT4 expression is critical for normal myeloid differentiation, but this normal event can be subverted by malignant hematopoietic cell transformation.
Thus, targeting PRMT4 represents a potential therapeutic approach to promote the differentiation of AML blast cells.
RESULTS

PRMT4 Regulates Myeloid Differentiation
To examine its function in hematopoiesis, we knocked down PRMT4 in human cord blood (CB)-derived, CD34
+ hematopoietic stem/progenitor cells (HSPCs), using lentiviral vectors that express GFP and short hairpin RNAs (shRNAs) directed against PRMT4. We assayed the extent of PRMT4 knockdown (KD) in the GFP-positive transduced cells and found a 70%-80% decrease in PRMT4 expression for the KD1 and KD2 short hairpin RNAs, respectively ( Figure 1A ). The PRMT4-KD cells generated far fewer CFUs when plated in methylcellulose (Figure 1B) and showed enhanced myeloid differentiation after 7 days in myeloid-promoting liquid culture (which contains stem cell factor [SCF], FLT-3 ligand, interleukin [IL]-3, IL-6, granulocyte-macrophage colony stimulating factor [GM-CSF], and granulocyte colony stimulating factor [G-CSF]) with 60%-70% of the KD cells being CD11b positive and CD13 positive, versus 40% (and 14%) of the control cells being CD11b (or CD13) positive (Figures 1C and S1B) . Consistent with the immunophenotypic evidence, morphologic evidence also showed more mature myeloid cells following PRMT4 KD ( Figure 1D ), with the KD cells showing a condensed nucleus and clear nuclear lobulation. In addition, PRMT4 KD mildly impaired erythroid differentiation under erythroid-promoting culture conditions (SCF and erythropoietin) ( Figure S1E ). Consistent with its effect on CFU generation, a decrease in the numbers and size of the cobblestone areas was seen at week 5, reflecting impaired HSPC self-renewal when PRMT4 was knocked down ( Figure S1D ).
We next examined whether PRMT4 overexpression blocks myeloid differentiation. Indeed, we found a marked reduction in CD11b-positive cells generated from PRMT4-overexpressing CD34 + cells (compared to the control cells) after 7 days in myeloid differentiation promoting cultures ( Figure 1E ). Thus, PRMT4 appears to be an important negative regulator of normal myeloid differentiation. Figure S1 .
PRMT4 Is
in myeloid-promoting liquid culture and observed a significant decrease in PRMT4 protein levels over a 7 day period ( Figure 2A ). PRMT4 mRNA levels varied only slightly during this process, suggesting that PRMT4 is being regulated posttranscriptionally. MicroRNA target prediction programs (TargetScan release 5.2 [ Figure S2A ] and PITA) suggested that PRMT4 is a potential target of several microRNAs, including miR-223, a myeloidspecific microRNA. Interestingly, a seed sequence for miR-223 is found in the 3 0 UTR region of PRMT4, which is located adjacent to the stop codon of the PRMT4 open reading frame (ORF) (16-22 nt from the stop codon); this location could confer a strong, translational regulatory effect (Grimson et al., 2007; Eulalio et al., 2008) . Indeed, we found that miR-223 expression steadily increases during myeloid differentiation ( Figure 2B ), concomitant with decreasing PRMT4 protein expression. To determine whether miR-223 regulates PRMT4 expression, we transiently transfected CD34 + cells with a short hairpin encoding the mature miR-223 for 24 hr and monitored PRMT4 expression, using siPRMT4 as a short-hairpin-positive control (and a scrambled short hairpin as a negative control). PRMT4 protein levels decreased by 50% in the miR-223-overexpressing cells, similar to that seen in the cells expressing small interfering RNA (siRNA) directed against PRMT4 ( Figure 2C ). To validate that PRMT4 is directly targeted by miR-223, we cloned its full-length 3 0 UTR into a luciferase reporter plasmid (UTR-WT), using the same construct with a mutated miR-223 targeting sequence (UTR-mut), which cannot bind miR-223, as negative control. We expressed these constructs in 293T cells, with either the miR-223 short hairpin or the control short hairpin and found that miR-223 decreased the luciferase activity of the UTR-WT, with no effect on the UTR-mut reporter plasmid (Figures 2D and S2C) . Thus, miR-223 directly targets PRMT4 by binding to its recognition sequence in the 3 0 UTR; this suggests that PRMT4 and miR-223 form a regulatory loop to regulate myeloid differentiation.
To determine how important the regulation of PRMT4 expression by miR-223 is for the effects of PRMT4 on myeloid differentiation, we overexpressed the PRMT4-ORF with either the WT or the mutant PRMT4 3 0 UTR, in human HSPCs. Although the WT 3 0 UTR abrogated the PRMT4 imposed block in myeloid differentiation, when PRMT4 was expressed without the 3 0 UTR, or with the mutant 3 0 UTR, the block in myeloid differentiation was seen ( Figure 2E ). These effects correlate with PRMT4 protein levels ( Figure 2F ) and demonstrate that the regulation of PRMT4 by miR-223 is important to its function during myeloid differentiation.
PRMT4 Represses miR-223 Expression
Given the known transcriptional regulatory role of PRMT4, to determine how PRMT4 controls myeloid differentiation, we first examined the expression level of several differentiation-specific ''master'' transcription factors, including PU.1, C/EBPa, KLF4, and GATA1 in PRMT4-KD cells. Although we found no significant changes ( Figure S3A ), we observed a consistent increase in miR-223 expression in the PRMT4-KD cells ( Figure 3A ). Because upregulation of miR-223 has been reported to promote the myeloid differentiation of leukemia cells (Fazi et al., 2007) , we overexpressed miR-223 in normal CB CD34 + cells, and saw a significant increase in CD11b-positive cells (51.2% versus 38.1% for the control cells) ( Figure 3B ) as well as decreased PRMT4 expression ( Figure S2B ). We observed decreased miR-223 expression, when PRMT4 is overexpressed ( Figure 3C ). When we knocked down miR-223 expression, we found a modest but consistent reduction in CD11b-positive cells (38.6% ± 3.1% versus 44.8% ± 1.8%, p < 0.05) (Figures 3D and S3B) , which suggests that other microRNAs may compensate for miR-223 during myeloid differentiation. This is consistent with the phenotype of miR-223 knockout mice, where miR-223 is important, but not essential, for granulocytic maturation and function (Johnnidis et al., 2008) . To determine whether PRMT4 regulates the transcription of miR-223, we quantified the level of miR-223 primary transcript (pri-miR-223) and found that PRMT4 expression does reciprocally regulate pri-miR-223 levels in CD34 + cells ( Figure S3C ). In addition, gene expression analysis of PRMT4 KD cells (GSE46056) revealed a gene signature consistent with an upregulation of myeloid differentiation ( Figure S3D ). Thus, PRMT4 regulates myeloid differentiation, at least in part, by modulating miR-223 expression. Figure S1 .
RUNX1 Is Methylated by PRMT4 on R223
PRMT4 is generally thought to act as a transcriptional coactivator; however, we found that PRMT4 functions as a repressor of miR-223 expression in hematopoietic cells. To determine how this ''coactivator'' suppresses gene expression, we hypothesized that PRMT4 modulates the activity of a regulatory transcription factor. Based on the report that the leukemogenic AML1-ETO fusion protein represses miR-223 expression via a RUNX1 consensus-binding site (CBS) in a specific regulatory region (Fazi et al., 2007) , we examined the miR-223 promoter and found another RUNX1 CBS close to the miR-223 promoter (Fukao et al., 2007) . Given the presence of these CBS, we investigated whether wild-type RUNX1 also regulates miR-223 transcription. We knocked down RUNX1 in CD34 + cells using two different shRNAs and observed upregulation of pri-miR-223 and pre-miR-223 expression ( Figure S4A ), indicating that RUNX1 can transcriptionally inhibit miR-223 expression in HSPCs. Given that both RUNX1 and PRMT4 repress miR-223 transcription, we examined whether RUNX1 is arginine methylated by PRMT4. Using an in vitro methylation assay, we identified one specific site in RUNX1, R223, which is methylated by PRMT4. This arginine residue is located just C-terminal to the RUNX1 DNA binding domain ( Figure S5A ) and is conserved among vertebrates ( Figure S5B ).
To determine whether RUNX1 is methylated at R223 by PRMT4 in vivo, we generated a methylation-specific methyl-R223RUNX1 antibody, which recognizes an asymmetric dimethylated R223RUNX1 peptide, but not the unmethylated peptide (data not shown). We confirmed the specificity of the antibody by overexpressing Flag-RUNX1 or the Flag-RUNX1R223K mutant protein in 293T cells with or without HA-PRMT4, or with an enzymatically dead form of PRMT4 (PRMT4EQ). Methylation of RUNX1 at R223 was strongly detected when both RUNX1 and PRMT4 were overexpressed ( Figure 4A, lane 1) or when RUNX1 was overexpressed by itself (lane 5). No methylation was detected when either the mutant R223K-RUNX1 protein was expressed or when PRMT4EQ was overexpressed ( Figure 4A, lanes 2-4) . Thus, we conclude that PRMT4 methylates RUNX1 at residue R223 in vivo. The same experiment showed the physical interaction between RUNX1 and PRMT4, using an HA antibody to detect PRMT4 in the RUNX1-containing immunoprecipitate; we detected an interaction between RUNX1 and PRMT4 when RUNX1 and PRMT4EQ were coexpressed or when the R223K-RUNX1 mutant was overexpressed with PRMT4 (or PRMT4EQ) (Figure 4A, IP lanes 2-4) . Minimal interaction was seen when RUNX1 overexpressed with WT-PRMT4 ( Figure 4A , IP lane 1), suggesting that PRMT4 preferably associates with the nonmethylated form of RUNX1. To determine whether PRMT4 is the major enzyme catalyzing RUNX1R223 methylation in vivo, we knocked down PRMT4 using siRNA in HEL cells; we observed a marked reduction in RUNX1 R223 methylation but no change in RUNX1 methylation at the RTAMR site, which we previously showed is methylated by PRMT1 ( Figure 4B ). Thus, PRMT4 appears to be the major methyltransferase that asymmetrically methylates RUNX1 at R223 in vivo.
Given the downregulation of PRMT4 protein levels during myeloid differentiation, we examined whether RUNX1R223 methylation is similarly downregulated, and indeed, as human CD34 + cells differentiate and PRMT4 expression diminishes, the level of methylR223-RUNX1 decreases, even though total RUNX1 protein levels are unchanged ( Figure 4C ). To determine whether R223 methylation is important for RUNX1 transcriptional activity, we compared the transcriptional regulatory activity of RUNX1 R223K versus WT-RUNX1 on the pri-mir-223 expression in CB CD34 + cells. Although RUNX1 overexpression repressed pri-miR-223 transcript levels, the RUNX1 R223K mutant did not ( Figure S4B) . Thus, the repression effects of PRMT4 on miR-223 expression appear to relate to its ability to posttranscriptionally modify RUNX1 on R223.
Methylation of RUNX1 at R223 Regulates Its Interaction with DPF2
We hypothesized that methylation of R223 in RUNX1 by PRMT4 affects its protein-protein interactions, and performed peptide (A) In vivo methylation of RUNX1 by PRMT4 was detected using a methyl-RUNX1-specific antibody. The full-length Flag-RUNX1 or Flag-RUNX1-R223K mutant cDNAs were overexpressed in 293T cells, with or without HA-tagged-WT-PRMT4, or an enzymaticallly dead PRMT4 mutant (PRMT4EQ). Immunoprecipitation was performed using a Flag antibody and immunoblotting with FLAG or HA antibodies. Wild-type RUNX1 (lanes 1 and 2), but not the R223K mutant protein (lanes 3 and 4) is methylated by wild-type PRMT4. The physical interaction between RUNX1 and PRMT4 is detected when RUNX1 is overexpressed with PRMT4EQ, but not WT-PRMT4, and when R223K is overexpressed with PRMT4 or PRMT4EQ (lanes 1-4 in the third row). Tubulin served as the loading control. (B) Knockdown of PRMT4 in HEL cells using siRNA reduces the level of endogenous methylR223-RUNX1, without altering total RUNX1 levels or the methylation of RUNX1 at the RTAMR motif. (C) The level of RUNX1R223 methylation decreases during myeloid differentiation, without changes in total RUNX1 expression but concordant with changes in PRMT4 protein levels. See also Figure S4. pull-downs using both a methyl-R223 RUNX1 peptide and an unmodified RUNX1 peptide as bait, followed by mass spectrometry, to identify proteins that interact with unmethylated or R223 methylated RUNX1 protein. We identified several proteins that interact with the R223 methyl peptide (Table  S1 ), including DPF2 (double PhD Finger 2), a widely expressed member of the d4 protein family that is characterized by the presence of a tandem plant homodomain (PHD domain). DPF2 was recently reported to interact with lysine-acetylated histones and acts as a corepressor (Matsuyama et al., 2010) . We first verified the interaction of DPF2 with the methyl-R223 RUNX1 peptide in a peptide pull-down assay: DPF2 preferentially bound to the arginine-methylated peptide, whereas PRMT4 preferred the nonmethylated RUNX1 peptide, similar to the interaction of PRMT4 with full-length RUNX1 ( Figure 5A ).
To determine whether RUNX1 and DPF2 associate in vivo, we performed coIP assays using two different RUNX1 antibodies and consistently immunoprecipitated the endogenous DPF2 protein, confirming their in vivo interaction ( Figure 5B ). To show that this interaction depends on arginine methylation, we treated HEL cells with adenosine-2 0 ,3 0 -dialdehyde (AdOx) (20 mM), a panmethyltransferase inhibitor, which significantly reduced RUNX1 methylation after 16 hr ( Figure 5D ). This treatment abrogated the interaction of RUNX1 with DPF2 ( Figure 5D , compare lane 2 and 4). To further demonstrate that DPF2 interacts specifically with R223-methylated RUNX1, we overexpressed Flag-RUNX1 and Flag-RUNX1R223K and performed coimmunoprecipitation studies using anti-Flag beads. DPF2 associated with Flag-RUNX1, but not Flag-RUNX1R223K ( Figure 5C , compare lanes 2 and 3), again demonstrating that the interaction of DPF2 with RUNX1 is dependent on the R223 methylation.
miR-223 Expression Is Regulated by a RUNX1-Methylation-Dependent Repressor Complex
Given the decrease in RUNX1R223 methylation during myeloid differentiation and the demonstrated interaction of R223-methylated RUNX1 with DPF2, we hypothesized that the DPF2-RUNX1 interaction regulates miR-223 expression. We examined the binding of RUNX1, PRMT4, and DPF2 to miR-223 regulatory regions by chromatin immunoprecipitation (ChIP) assays using HSPCs and in vitro differentiated myeloid cells, which correspond to the states where miR-223 is low and RUNX1 R223 methylation high (i.e., the HSPC stage), and where miR-223 is high, and RUNX1 R223 methylation low (i.e., in differentiated myeloid cells) ( Figures 6A and 6B ). Using primer pairs that cover much of the miR-223 putative regulatory regions (as depicted in Figure 6C and Table S2 ), we detected RUNX1, methyl-R223 RUNX1, and DPF2 at the pre-miR-223 promoter region, when the cells were at the ''stem/progenitor'' stage and miR-223 was minimally expressed ( Figure 6D ). However, in the differentiated cells where miR-223 was actively transcribed, we found RUNX1 and not methyl-R223 RUNX1 ( Figure 6E ). PRMT4 is found throughout the miR-223 regulatory region in the HSPCs but not in the differentiated cells, with a slight peak at region 4. DPF2 protein is clearly expressed in the differentiated cells ( Figure 6A ), but it is not found at the miR-223 regulatory regions ( Figure 6E ), suggesting that its recruitment to the miR-223 promoter depends on the methylation status of RUNX1. Thus, recruitment of DPF2 by methyl-R223 RUNX1 may dictate the transcriptional effects of RUNX1 on the miR-223 locus.
DPF2 Inhibits miR-223 Expression and Myeloid Differentiation
We next examined whether DPF2 can directly regulate miR-223 expression. We achieved a 50% knockdown of DPF2 mRNA and protein using shRNA ( Figure 6F ) and found a 3-fold increase in miR-223 expression ( Figure 6G ) and a decrease in PRMT4 protein levels. The DPF2 KD cells also showed enhanced myeloid differentiation (based on CD11b expression, Figure 6H ) and decreased clonogenic potential ( Figure S6 ) similar to what (A) DPF2 is preferably pulled down by a methylR223-RUNX1 peptide, whereas the unmodified R223-RUNX1 peptide interacts more strongly with PRMT4. BAF155 is used as a control, which shows no preference for binding to either the modified or the unmodified peptide. Input: 10% of the used nuclear extract. (B) The endogenous RUNX1 and DPF2 proteins physically interact in vivo. Two RUNX1 antibodies were used to immunoprecipitate DPF2 from HEL cell nuclear extract. DPF2 was detected using a DPF2 antibody. Preimmune rabbit serum was used as control. occurred when we knocked down PRMT4. This places PRMT4 and DPF2 in a RUNX1 containing complex that downregulates miR-223 expression and impairs the myeloid differentiation of HSPCs.
Knockdown of PRMT4 Is Sufficient to Induce Myeloid Differentiation in AML Cell Lines As PRMT4 expression impairs the differentiation of human HSPCs, we examined the level of PRMT4 expression in a cohort of 318 AML patient samples (GSE24505) (Figueroa et al., 2010) . PRMT4 levels were significantly upregulated in the AML samples, compared to the control group (n = 5) ( Figure 7A) . A high level of PRMT4 expression was seen in core-binding factor (CBF) AMLs (which express either AML1-ETO or CBFb-SMMHC), which exhibit low-level miR-223 expression, but, overall, about 70% of the AML patients had at least a 2-fold increase in PRMT4 expression ( Figure S7A ). Several studies have shown that overexpression of miR-223 can promote the granulocytic differentiation of NB4 acute promyelocytic leukemia (APL) cells (Fazi et al., 2005) . We knocked down PRMT4 in NB4 cells and triggered myeloid differentiation with a significant increase in the number of CD11b-positive cells (3.3% control versus 23.8% and 47.3%) ( Figure 7B ) as well as changes in cellular morphology and an upregulation of miR-223 expression ( Figures S7B and S7C) . A similar induction of differentiation was also observed in the ATRA-resistant NB4-R4 cells following PRMT4-KD (Rosenauer et al., 1996) (Figures S7D and S7E ). Because therapeutic targeting of most leukemia fusion proteins, including AML1-ETO remains elusive, we tested whether targeting PRMT4 can promote the differentiation of AML1-ETO-expressing cells (Figure 7A) . We knocked down PRMT4 in t(8;21)-positive Kasumi-1 cells and found increased differentiation ( Figures 7C and S7E) . We also saw significant apoptosis of all three cell lines when PRMT4 is knocked down (Figure S7F ), suggesting that PRMT4 not only impairs the differentiation of these leukemia cells, but it is also critical for their survival.
Knockdown of PRMT4 Reduces the Leukemia Burden In Vivo
To investigate the in vivo role of PRMT4 in leukemogenesis, we used shRNA-expressing lentiviruses to knock down PRMT4 in the AML1-ETO9a (AE9a)-driven mouse AML model (Yan et al., 2006; Wang et al., 2011) . Leukemia cells growing in culture were transduced with two different shRNAs, and R70%-80% KD was achieved ( Figure S7G ). The transduced AE9a-mPRMT4KD and control cells were injected into sublethally irradiated C57Bl/6 mice (day 0). We observed decreased numbers of immature GFP + c-kit + blast cells in the peripheral blood of the AE9a-mPRMT4KD mice compared to the control mice at week 3 ( Figure 7D ). Morphological analysis of the bone marrow ( Figure 7E ) and peripheral blood ( Figure S7I ) also showed a marked reduction in blast cells at week 4 with lower white blood cell counts, and less anemia and thrombocytopenia ( Figure S7H ), compared to the AE9a-control mice. This translated to a significant increase in median survival, from 28 days for the control group, to 51 days and 64.5 days for the AE9a-mPRMT4-KD1 and AE9a-mPRMT4-KD2 groups, respectively (p < 0.0001; Figure 7F ). This demonstrates an important role for PRMT4 in leukemogenesis and identifies it as an important therapeutic target.
DISCUSSION
We have found that PRMT4 is highly expressed in HSPCs, where it functions as an inhibitor of myeloid differentiation ( Figure 7G ). In these cells, PRMT4 methylates RUNX1 at R223, promoting the assembly of a DPF2-containing transcriptional corepressive complex and repressing transcription at the miR-223 locus. As HSPCs undergo myeloid differentiation, PRMT4 expression decreases, reducing the amount of R223-methyl RUNX1, which, in turn, decreases the presence of DPF2 at the miR-223 promoter region, thereby allowing miR-223 to be transcribed. The ability of miR-223 to target the 3 0 UTR of PRMT4 allows the further upregulation of miR-223 expression, which further decreases PRMT4 and sustains the myeloid differentiation process. Although PRMT4 promotes differentiation in several biological systems including T cell, adipocyte, and muscle development, it blocks differentiation in the hematopoietic system, allowing HSPCs to maintain stemness. This role is consistent with its role in embryonic stem cells, where PRMT4 functions to maintain pluripotency (Torres-Padilla et al., 2007; Wu et al., 2009) . The changes in PRMT4 expression and miR-223 during myeloid differentiation allowed us to define a link between an arginine methyltransferase and the expression of a microRNA (miR-223), with PRMT4 and miR-223 forming a regulatory loop to influence myeloid differentiation. MicroRNAs that target enzymes involved in epigenetic regulation are being identified, and PRMT4 can join the list of targets, which thus far includes Dnmt3A (miR-29) (Fabbri et al., 2007; Garzon et al., 2009 ) and EZH2 (miR-101) (Varambally et al., 2008) . Although we have identified the specific sequence in the PRMT4 3 0 UTR that contributes to its regulation by miR-223, the 3 0 UTR region of PRMT4 has binding sequences for other microRNAs that could also target its expression. Whether these microRNAs also contribute to the regulation of PRMT4 during hematopoiesis will require further study.
The initial signals that trigger the downregulation of PRMT4 expression, which helps drive the process of myeloid differentiation, remain to be determined. Once the decrease in PRMT4 activity occurs, increased expression of miR-223 (and likely other targets of the methyl-RUNX1 repressor complex) occurs, which can further downregulate PRMT4 protein levels and activity, and promote differentiation. This regulatory feedback loop therefore pushes the differentiation process forward. It is known that PRMT4 enzymatic activity can be regulated by posttranslational modifications (Cheung et al., 2008; Higashimoto et al., 2007) ; thus, upstream signaling pathways (such as PI3K/AKT; Supplemental Results) could control PRMT4 enzymatic activity and expression.
A fundamental aspect of transcriptional regulation has been to define how a given protein can function either as an activator or a repressor. We have recently shown that AML1 (RUNX1)-ETO, a well-known leukemia-associated TF fusion protein generally thought to function as a transcriptional repressor, has activator functions as well that are critical to its leukemogenic properties . Our study of PRMT4 provides further evidence for a flexible model of how proteins regulate gene expression. PRMT4 has been thought of as a ''secondary'' coactivator molecule that helps activate transcription of its target genes via methylation of histone H3. We have identified a transcriptional repressor function for PRMT4 and provide a molecular basis for this function, which involves the methylation of a nonhistone substrate, namely RUNX1. The interaction of PRMT4 with RUNX1 appears to be transient, i.e., a kind of ''hit and run.'' However, the recruitment of PRMT4 to the chromatin of its target genes could be more stable, either due to its binding histones or other chromatin associated factors.
It is clear that RUNX1 can assemble a variety of multiprotein complexes that affects its transcriptional regulatory functions. These complexes are regulated by various posttranscriptional modifications. The association of RUNX1 with mSIN3A is disrupted by the PRMT1-dependent methylation of RUNX1 on R206 and R210 (Zhao et al., 2008) . Similarly, the methylation of C/ EBPb by PRMT4 interfered with its association with both the SWI/SNF and Mediator complexes (Kowenz-Leutz et al., 2010).
In contrast to that model, we show that the methylation of RUNX1 by PRMT4 actually promotes protein-protein interactions.
We found the preferential binding of DPF2 to R223-methylated RUNX1 and that, by recruiting DPF2, RUNX1 can repress miR-223 expression. This function of DPF2 is consistent with its ability to act as a cosuppressor of nuclear receptor-mediated transcription regulation, by binding HDAC1 (Matsuyama et al., 2010) . Although DPF2 has been implicated in transcriptional regulation, little is known about its biological functions. Here, DPF2 appears to be another important regulator of myeloid differentiation that can cooperate with PRMT4 to maintain the ''stemness'' of HSPCs. As both PRMT4 (Torres-Padilla et al., 2007; Wu et al., 2009 ) and DPF2 are expressed in ES cells (Ho et al., 2009) , they may also cooperatively regulate gene expression in ES cells.
Targeting of the differentiation (and apoptotic) processes has become a promising therapeutic approach in the treatment of hematologic malignancies like AML, which are characterized by a block in differentiation. We were able to differentiate myeloid leukemic cells by knocking down PRMT4 and observed this effect even in ATRA-resistant cell lines. By utilizing the AML1-ETO driven leukemia model, we showed that knocking down of PRMT4 not only induced myeloid differentiation but also triggered apoptosis, leading to improved survival in an in vivo mouse AML model. These findings strongly suggest that targeting PRMT4 function could hold potential as a novel therapy of acute myelogenous leukemia.
EXPERIMENTAL PROCEDURES
Purification, Infection, and Culture of HSPC-CD34 + Cells CD34 + HSPCs were purified by positive selection using the Midi MACS (magnetic-activated cell sorting) LS + separation columns and isolation Kit (Miltenyi) starting with mononuclear cells that were isolated from cord blood (CB) by Ficoll-Hypaque Plus density centrifugation. CD34 + cells were cultured in Iscove's modified Dulbecco's medium (IMDM, Cellgro) 20% BIT 9500 medium (STEMCELL Technologies) supplemented with SCF (100 ng/ml), FLT-3 ligand (10 ng/ml), IL-6 (20 ng/ml), and TPO (100 ng/ml) as the basic culture. CD34 + cells were infected with high-titer lentiviral concentrated suspensions, with 8 mg/ml polybrene (Sigma-Aldrich). To differentiate HSPCs, cells were cultured under the myeloid-promoting conditions: SCF (100 ng/ml), FLT-3 ligands (10 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), GM-CSF (20 ng/ml), and G-CSF (20 ng/ml) and the erythroid-promoting conditions Epo (6 IU/ml) and SCF (100 ng/ml). Cytokines were purchased from PeproTech.
Peptide Pull-Down Assay Methylated (Acetyl-TPNPR [Asymmetric-dimethyl] ASLNHS-C-amide) and nonmethylated (Acetyl-TPNPRASLNHS-C-amide) peptides were synthesized, quantified, and conjugated to SulfoLink agarose (Pierce). For each pull-down reaction, 10 mg of HEL cell nuclear extract was used with 10 mg peptide bound beads in H lysis buffer (20 mM HEPES [pH 7.9], 150 mM NaCl, 1 mM MgCl 2 , 1% NP40, 10 mM NaF, 0.2 mM NaVO 4 , 10 mM b-glycerol phosphate, 5% glycerol) with freshly added 1 mM DTT and proteinase inhibitor cocktail (Roche).
After rotating overnight at 4 C, the beads were washed five times with the binding solution. The bound protein was then eluted with 1 3 SDS sample buffer and analyzed on 4%-12% NUPAGE gels.
ChIP Assays
Approximately 4 3 10 6 cells were used per ChIP reaction after crosslinking with 1% formaldehyde for 10 min at room temperature. ChIP assays were performed according the previously reported methodology (Zhao et al., 2008) .
After purification, the associated DNA was subjected to quantitative RT-PCR (qRT-PCR) to detect specific DNA sequences. Quantitative results are represented as percentages relative to 5% DNA input. Table S2 provides primer sequences.
In Vivo Transplantation of AE9a Leukemia Cells AE9a-expressing mouse leukemia cells were generated based on the work of Wang et al. (2011) . These cells were transduced with lentiviruses expressing RFP and shRNAs against PRMT4 or a scrambled control shRNA. Transduced cells were sorted for RFP positivity, and 10 5 -sorted cells were injected into female C57Bl/6 recipient mice that has been sublethally irradiated with 475 cGy via tail vein. All animal studies were performed on IACUC approved animal protocols.
Statistic
Statistical analyses were carried out using Prism 5.0 for Macintosh. All data are shown as mean ± SD. The mean values of each group were compared by Student's t test.
ACCESSION NUMBERS
RNA sequencing data has been deposited in the NCBI Gene Expression Omnibus under accession number GSE46056. 
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